France-based biotech developer Scipio Bioscience received €1.2m ($1.4m) in seed funding on Tuesday from investors including multi-university venture fund Quadrivium I, managed by Seventure Partners.
The round also included German public-private partnership High-Tech Gründerfonds.
Scipio aims to create test tube preparation technology for single-cell research with ribonucleic acids (RNA). RNA molecules are essential to a person’s genetic code and hold great potential for genomics research, however the cost of sequencing experiments can be prohibitive.
Scipio’s approach would use an automated…
